AstraZeneca PLC
camizestrant
HR-positive, HER2-negative advanced breast cancer
Resolved
102days ago
FDA decision · Mar 27, 2026
What's at stake
The FDA's approval decision on camizestrant for HR-positive, HER2-negative advanced breast cancer is due Mar 27, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 6-K
verified 14h ago
“The US Food and Drug Administration (FDA) has informed AstraZeneca that it will extend the Prescription Drug User Fee Act (PDUFA) date to review additional data requested to support the New Drug Application (NDA) for camizestrant in combina”